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Background: l-Asparaginase is essential in the treatment of childhood acute lymphoblas-
tic  leukemia. If immunoglobulin G anti-l-asparaginase antibodies develop, they can lead
to  faster plasma clearance and reduced efﬁciency as well as to hypersensitivity reactions,
in  which immunoglobulin E can also participate. This study investigated the presence of
immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies and their clinical
associations.
Methods: Under 16-year-old patients at diagnosis of B-cell acute lymphoblastic leukemia
conﬁrmed by ﬂow cytometry and treated with a uniform l-asparaginase and chemotherapy
protocol were studied. Immunoglobulin G anti-l-asparaginase antibodies were measured
using an enzyme-linked immunosorbent assay. Intradermal and prick skin testing was
performed to establish the presence of speciﬁc immunoglobulin E anti-l-asparaginase anti-
bodies in vivo. Statistical analysis was used to investigate associations of these antibodies
with relevant clinical events and outcomes.
Results: Fifty-one children were studied with 42 (82.35%) having anti-l-asparaginase anti-
bodies. In this group immunoglobulin G antibodies alone were documented in 10 (23.8%)
compared to immunoglobulin E alone in 18 (42.8%) patients. Immunoglobulin G together
with immunoglobulin E were simultaneously present in 14 patients. Children who pro-duced exclusively immunoglobulin G or no antibodies had a lower event-free survival
(p-value = 0.024). Eighteen children (35.3%) relapsed with ﬁve of nine of this group who had
negative skin tests suffering additional relapses (range: 2–4), compared to none of the nine
children who relapsed who had positive skin tests (p-value < 0.001).
∗ Corresponding author at: Ediﬁcio “Dr. Rodrigo Barragán” 2◦ piso, Hospital Universitario “Dr. José E. González” Avenida Madero y Gonzalitos
S/N,  Colonia Mitras Centro, Monterrey, Nuevo León, C.P. 64460, Mexico.
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http://dx.doi.org/10.1016/j.bjhh.2016.11.006
1516-8484/© 2017 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Conclusion: Children with acute lymphoblastic leukemia and isolated immunoglobulin G
anti-l-asparaginase antibodies had a higher relapse rate, whereas no additional relapses
developed in children with immunoglobulin E anti-l-asparaginase antibodies after the ﬁrst
relapse.
©  2017 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by  Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
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tEscherichia coli l-asparaginase is key in the treatment
f childhood acute lymphoblastic leukemia (ALL).1 High-
ntensity l-asparaginase regimens result in better outcomes
han lower-dose schemes.2 The intravenous or intramus-
ular route can be used to administer l-asparaginase; the
atter is well tolerated and does not appear to result in
ncreased hypersensitivity reactions3 whereas the former
s more  immunogenic.4 More  recently it was shown that
he intravenous administration of pegylated l-asparaginase
s also associated with a higher risk of allergic reactions.5
he l-asparaginase molecule is highly reactive, has a com-
lex quaternary structure and elevated molecular weight
nd it can elicit production of immunoglobulin (Ig)G anti-l-
sparaginase antibodies. These antibodies can cause severe
llergic and hypersensitivity reactions, albeit rarely fatal,
n children suffering a severe reaction, mostly mediated
y IgG and complement.3,6 In these cases, substitution for
-asparaginase conjugated covalently with 5000 molecular
eight polyethylene glycol is indicated, although one third
f those switched to the pegylated enzyme still have allergic
eactions due to the fact that the source of both preparations
s the same bacterium.7,8 Interestingly, treatment with the
nzyme derived from Erwinia chrysanthemi, which can substi-
ute the typical variety of Escherichia coli, may not be necessary
or some children with severe allergies to E. coli l-asparaginase
ho  have received at least half of intended doses.9 Important
spects for better therapeutic results and less frequent side
ffects include new sources of l-asparaginase to increase its
vailability, improved pharmacodynamics and pharmacoki-
etics and safer toxicological proﬁle.10
Decreased efﬁcacy of l-asparaginase due to high titers
f IgG antibodies may be due to neutralizing antibodies,
ncreased enzyme clearance, delayed absorption after intra-
uscular administration, and direct interference with its
nzymatic activity.11
Currently, there are no commercially available, clinically
alidated assays for IgG or IgE anti-l-asparaginase antibodies.
oreover, the speciﬁcity of anti-l-asparaginase antibodies to
redict inactivation has been low in comparison to measuring
-asparaginase activity itself; many  patients develop anti-l-
sparaginase antibodies without clinical allergic reactions or
nactivation of the enzyme, and antibody levels in children
ith and without hypersensitivity overlap.12
Importantly, no correlation has been found between IgG
ntibody titers and the severity of the allergic reaction.13 This
s probably because IgG anti-l-asparaginase antibody assays
re used as a surrogate for the diagnosis of l-asparaginase
llergy, and non-allergic ALL children can develop speciﬁc
gG anti-l-asparaginase antibodies, rendering its diagnos-
ic utility controversial.14 Speciﬁc IgE anti-l-asparaginase(http://creativecommons.org/licenses/by-nc-nd/4.0/).
antibodies, on the other hand, contribute to clinical
symptoms through mediator release from mast cells.15
Thus, controversy on the meaning of anti-l-asparaginase
antibodies remains although its prognostic signiﬁcance and
clinical utility has been studied for over 30 years.16 Several
important questions remain, including what is the association
between IgE anti-l-asparaginase antibodies and ALL clinical
events other than allergic reactions. Furthermore, the time
during which IgG and IgE antibodies can be detected has not
been established.
This study investigated the production of IgG and IgE anti-
l-asparaginase antibodies in children diagnosed with B cell
ALL treated with a standardized dose of E. coli l-asparaginase
and determined the association of these two antibodies with
the clinical course and risk of relapse.
Methods
A transversal descriptive cross-sectional study was conducted
in the Hematology, Allergy, and Immunology Departments, of
the “José Eleuterio González” University Hospital of the Uni-
versidad Autónoma de Nuevo León, Monterrey, Mexico. Under
16-year-old patients with diagnosis of B-cell ALL conﬁrmed
by ﬂow cytometry at any stage of treatment after induction
to remission therapy were included. Children taking anti-
H1 or anti-H2 antihistamines were excluded. The study was
approved by the Institutional Review Board and Ethics Com-
mittee of the institution and parents signed informed consent
forms.
Induction to remission therapy consisted of prednisone
60 mg/m2, vincristine 1.5 mg/m2, and six doses of l-
asparaginase of 6000 IU/M2/intramuscular on Days 8, 12, 16,
20, 24, and 36. Children with high-risk ALL received two  addi-
tional doses of l-asparaginase on Days 2 and 8 of re-induction
and three doses of doxorubicin (40 mg/m2); triple intrathecal
chemotherapy for central nervous system (CNS) prophylaxis
was administered four times. Consolidation included single
doses of cytosine arabinoside (1.5 g/m2) and methotrexate
(1.5 g/m2) administered in a one-day intravenous infusion.
This was followed by one month of 6-mercaptopurine taken
daily and weekly methotrexate. Re-induction included 15 days
of prednisone, three doses of vincristine, two of doxorubicin
for high-risk and one for standard-risk patients, two doses of
l-asparaginase and two of triple intrathecal prophylaxis. Ten
days after re-induction, maintenance was started for 90 weeks
with oral 6-mercapthopurine at 50 mg/m2/day and weekly
methotrexate starting at 30 mg/m2/day and adjusted to main-
tain the absolute leukocyte count between 3.0 and 5.0 × 103/L.
Every six weeks during the ﬁrst year of maintenance, and
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every three months during the second year, maintenance
was suspended for a week in order to administrate one
single dose of vincristine, triple intrathecal chemotherapy,
and seven days of prednisone; this regimen was inspired
on a previously published protocol.17 Prophylaxis of the CNS
consisted in triple intrathecal therapy including cytosine ara-
binoside, methotrexate, and hydrocortisone. CNS irradiation
was reserved for patients with inﬁltration at diagnosis and
those suffering CNS relapse. Relapsed children received addi-
tional l-asparaginase if they did not develop clinically evident
hypersensitivity manifestations.
Immunoglobulin  G  anti-l-asparaginase  antibody
determination
IgG anti-l-asparaginase serum antibodies were determined
employing an enzyme-linked immunosorbent assay (ELISA)
following a previously reported method.18 Brieﬂy, periph-
eral blood collected from patients and ten healthy controls
was centrifuged for ﬁve minutes at 3000 rpm and the sepa-
rated serum was stored at −70 ◦C. Leunase, 10,000 IU (Kioto,
Japan) was diluted in 0.05 M carbonate-bicarbonate buffer (pH
9.4–5 g/mL); 100 L of this dilution were added, in dupli-
cate, to 96-well polystyrene ELISA plates (WWR  Scientiﬁc
Product, GA, USA) followed by overnight incubation at 4 ◦C.
The supernatant was discarded and the plates were washed
with phosphate buffered saline (PBS) containing Tween-20,
0.1%. Phosphate buffered saline (300L), containing 0.5% bovine
serum albumin (BSA) (Sigma, St. Louis, MO, USA), 5% fetal
bovine serum and 0.1% Tween-20, was added to each well,
followed by an incubation of 90 min  at room temperature
(RT); excess supernatant was discarded and the wells were
washed three times with the PBS/tween-20 solution. For the
assay, 100 L of plasma of patients and controls, diluted
1:3200 in saline-tween were added in duplicate to a 96-well
polystyrene plate to which l-asparaginase was previously
attached, as described above,18 including negative and pos-
itive controls. As no severe or anaphylactic reactions to
l-asparaginase developed in the children of this study, pos-
itive IgG anti-l-asparaginase control serum was obtained
from sensitized mice. Brieﬂy, 15 mg  of Leunase (Kyowa Hakko
Kogyo Co., Japan) in incomplete Freund adjuvant solution
was injected into the peritoneum of Balb/c mice between
six and eight weeks of age. Additional immunizations were
given on Days 15 and 30 injecting 10 mg of the enzyme in the
same Freund solution. On Day 35 post-immunization, blood
was taken from the retro-orbital vascular plexus and cen-
trifuged at 3000 rpm; ﬁnally, mice sera were pooled and tested;
the mixed serum with the highest IgG anti-l-asparaginase
titer, as assayed above, was the positive control. Negative
controls consisted of sera from non-immunized mice, nor-
mal  human sera, and diluent alone. Plates were incubated
with continuous agitation at 37 ◦C for one hour; the super-
natant was discarded and the wells washed three times with
saline-Tween-20; 150 L of a secondary peroxidase-conjugated
monoclonal goat anti-human IgG antibody (Sigma, St. Louis,
MO, USA) was added to each well and incubated at 37 ◦C for
one hour. Four washes were followed by the addition to each
well of 100 L of a substrate-chromogen solution containing
o-phenylenediamine dihydrochloride (OPD):2HCl (Sigma, St. 2 0 1 7;3  9(3):202–209
Louis, MO, USA), hydrogen peroxide, and citrate buffer, then
incubated for 30 min  at room temperature in the dark. The
reaction was stopped by adding 100 L of a 1.0 M phosphoric
acid solution; l-asparaginase antibodies were expressed as
optical density (OD) readings. Samples were deﬁned as posi-
tive if the natural log of the 1:3200 OD reading was greater than
two standard deviations above the negative control processed
mean.19
Immunoglobulin  E  anti-l-asparaginase  antibody  detection
Due to the lack of a commercially available standardized
assay for IgE anti-l-asparaginase antibodies, we  decided to
assess IgE-mediated type I hypersensitivity reaction to l-
asparaginase in vivo. Thus, two types of validated skin testing
were performed, a prick skin test (PST)20 and intradermal skin
test (IST).21 The PST was carried out by applying one drop
of a 30 M l-asparaginase solution (Leunase, Kyowa Hakko
Kogyo Co., Japan) followed by a skin puncture using a dis-
posable plastic lancet (Duotip® by Lincoln Diagnostic, Inc.,
Decatur, IL). The solution was left in contact with the skin for
15 min. Afterwards the papule and erythema were observed
and the diameter was measured in millimeters by the same
experienced allergist in all cases using a millimeter scale. The
IST was performed by injecting 10 L of the same sterile l-
asparaginase solution; after 15 min, the papule and erythema
were measured in millimeters in the same way as for the PST.
An intradermal injection of 10 L of 1% histamine phosphate
solution was the positive control for the skin test; normal
saline solution was the negative control. A wheal of 3 mm or
larger than the negative control was interpreted as a positive
test.20
Statistical  analysis
The Chi-square test was used to analyze frequencies, the
Mann–Whitney test for independent variables with non-
normal distribution, and Spearman’s method were used to
study IgG–IgE correlations. The Kaplan–Meier method was
used to compare event-free survival (EFS) between children
who did and did not have IgG antibodies, and between those
with and without an IgE response to l-asparaginase as eval-
uated using the PST and IST. The Statistical Package for the
Social Sciences (SPSS – v20) was employed.
Results
Fifty-one patients were studied; pertinent descriptive data are
shown in Table 1. Children received a median of eight doses
(range: 5–14) of l-asparaginase. According to the clinical ﬁles
and electronic records, only three (5.8%) patients suffered any
allergic/hypersensitivity reaction consisting of urticaria/skin
rash after receiving 8, 8, and 13 l-asparaginase doses, respec-
tively; there were no anaphylactic reactions.
In total 42/51 (82.35%) patients had IgG, IgE, or both anti-
l-asparaginase antibodies; ten (23.8%) had exclusively IgG
antibodies, whereas 18 (42.86%) had exclusively IgE antibod-
ies; of the forty-two children with antibodies, IgG was present
in 24 (57.14%), and IgE in 32 (76.19%); 14/42 (33.33%) developed
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Table 1 – Important characteristics of 51 children with
acute lymphoblastic leukemia.
Characteristic
Age, years – median (range) 8 (4–17)
Gender – n (%)
Male 27 (53)
Female 24 (47)
Risk group – n (%)
Standard-risk 23 (45.1)
High-risk 28 (54.9)
Clinical status at the time of the study – n (%)
Maintenance (≥1 year) 27  (52.9)
Surveillance 16 (31.3)
Relapse 8 (15.6)
Anti-l-asparaginase antibodies – n (%)
IgG (ELISA) 24 (47.0)
IgE (in vivo)  18 (35.3)
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Figure 2 – Event-free survival was signiﬁcantly lower
among children who produced only immunoglobulin (Ig)G
anti-l-asparaginase antibodies and those with no
antibodies compared to children with IgE antibodies in
isolation or combined with IgG antibodies.None 9 (17.7)
oth IgG plus IgE antibodies. No IgG or IgE antibodies were
ound in 9/51 (17.64%) children.
With regard to associations between risk group and
ntibodies, 19/23 (82.6%) standard-risk patients developed
ntibodies compared to 23/28 (81.2%) high-risk children (p-
alue > 0.05). When antibody distribution was studied it was
ound that six (21.4%) high-risk patients developed IgG anti-
odies, compared to four (17.4%) in the standard-risk group,
hile IgE antibodies were detected in 13 (46.4%) vs. ﬁve (21.7%),
nd IgG together with IgE antibodies in four (14.3%) vs. ten
43.46%) high-risk and standard-risk children, respectively (p-
alue = 0.38).
No difference was documented in EFS for ALL children with
gG and IgG plus IgE anti-l-asparaginase antibodies (n = 24)
s. those with no antibodies or with IgE alone (n = 27 – p-
alue = 0.774; Figure 1).
Neither the presence nor the titer of IgG anti-l-
sparaginase antibodies inﬂuenced the response to induction
r re-induction to remission therapy (p-value = 0.19). Fur-
hermore, no difference in response to ALL induction or
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igure 1 – No difference was found in the event-free
urvival of acute lymphoblastic leukemia children with
mmunoglobulin (Ig)G and IgG plus IgE anti-l-asparaginase
ntibodies vs. IgE antibodies and no antibodies.re-induction therapy was documented between children with
a positive or a negative skin test (p-value = 0.82). Table 2 com-
pares the type and prevalence of antibodies in the current
study sample with the results of reports in the literature.
Prick skin testing was performed in all 51 children with 28
(54.9%) having positive results; 23 (45.1%) patients with nega-
tive PST were submitted to IST with only four having positive
results. Thus, 32 (62.7%) of 51 children had speciﬁc IgE anti-l-
asparaginase antibodies demonstrated by a positive skin test
in vivo.
Eighteen (35.3%) patients of the whole group relapsed, two
(8.7%) of the 23 standard-risk children and 16 (57.1%) in the 28
high-risk group (p-value < 0.001).
The EFS of the 19 patients who developed IgG anti-l-
asparaginase antibodies only and those with no antibodies
was signiﬁcantly lower than in the remaining 32 patients,
[36 months (range: 27–40) vs. 96 months (range: 62–99); p-
value = 0.024 – Figure 2].
No statistically signiﬁcant difference in EFS was doc-
umented for children with no antibodies (n = 9) against
l-asparaginase compared to those having IgG, IgE or both
(n = 42) antibodies (p-value = 0.583 – Figure 3).
Eighteen (35.3%) patients relapsed at a median of 20.5
months (range: 1–96), ten relapsed during ﬁrst maintenance,
ﬁve after cessation of therapy, and three several years after
completing treatment. Nine (50%) had exclusively IgG anti-
l-asparaginase antibodies and nine (50%) had positive skin
tests indicating the presence of IgE anti-l-asparaginase anti-
bodies, none had both. Fifty-ﬁve percent (5/9) of the children
who relapsed who had IgG, but not IgE detectable by skin
testing, suffered additional relapses (range: 2–4). In contrast,
none of the nine patients who relapsed and had a positive
skin test suffered additional relapses (p-value < 0.01). Thus,
patients with negative skin tests had a multiple-relapse haz-
ard ratio of 2.87 (95% conﬁdence interval: 1.041–7.944; p-value =
0.042).
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Table 2 – Anti-l-asparaginase antibodies identiﬁed in this study and in representative publications.
Reference n IgG IgE IgG + IgE IgM None
Current study 51 10 (19.6%) 18 (35.3%) 14 (27.5%) 9 (17.6%)
Panosyan et al.1 1001 611 (61.0%) 390 (39.0%)
Zalewska-Szewczyk et al.8 13 5 (38.5%) 8 (61.53%)
Woo et al.13 152 54 (35.5%) 98 (64.5%)
Zalewska-Szewczyk et al.14 47 20 (42.5%) 19 (40.4%) 8 (17.0%)
Cheung et al.16 13 7 (53.8%) 6 (46.2%)
Kawedia et al.19 35 28 (80.0%) 7 (20.0%)
Ig: Immunoglobulin.
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Figure 3 – No signiﬁcant difference in event-free survival
was found for acute lymphoblastic leukemia children with
no antibodies compared to those with immunoglobulin
(Ig)G, IgE or both IgG and IgE anti-l-asparaginase
antibodies.
cells. After re-exposure, mast cells proliferate and releaseDiscussion
The relevance of antibodies directed against l-asparaginase
in children with ALL has been consistently highlighted in
the Berlin–Frankfurt–Münster (BFM) studies and recently
reviewed.8,12 Adverse reactions to the enzyme can be medi-
ated by IgG, complement or IgE antibodies, or more  than
one at the same time.22 A neutralizing nature of IgG anti-
l-asparaginase antibodies leading to accelerated plasmatic
clearance, with an important decrease in l-asparaginase
activity, has been reported23; the titer of these antibodies
can increase considerably after switching to pegylated l-
asparaginase following the development of hypersensitivity.24
Interestingly, the different roles of these anti-l-asparaginase
antibody classes and their correlation with clinical allergy
manifestations and the development of silent antibodies has
not been discussed.
Allergic reactions are associated with the appearance
of antibodies, which have been reported to increase l-
asparaginase clearance and to reduce or even neutralize the
catalytic activity of the enzyme.14,25 ALL patients who develop
anti-l-asparaginase antibodies may thus have poor outcomes
because of low l-asparaginase activity.14,19A report on the diagnostic utility of serum antibody test-
ing in 410 children with ALL receiving l-asparaginase found
that 169 (41.2%) had some degree of clinical allergy and 148
(87%) had IgG anti-l-asparaginase antibodies; of the remaining
241 patients with no allergy, 89 (36.9%) had IgG antibodies. IgE
antibodies were not determined.26
The goal of the current study was to investigate the pres-
ence of both IgG and IgE antibodies to l-asparaginase and
to explore their clinical correlation with the course of the
disease. Over 80% of children developed antibodies, almost
60% of these were IgG and only these were associated to
lower EFS most probably due to their l-asparaginase neutral-
izing nature; the incidence of anti-l-asparaginase antibodies
in this study sample (82.35%) was similar to the 87% reported
in a large prospective study.27 Remarkably, IgG and IgE anti-
bodies were detected in some cases several years after the
patient’s last exposure to the enzyme thus conﬁrming that
l-asparaginase is strongly immunogenic and that immune
memory  mechanisms are active and operational during the
evolution and therapy of ALL. It is important to point out
that current recommendations state that anti-asparaginase
antibody and asparagine measurements are not indicated
for clinical decision making outside the context of clinical
trials.12
Furthermore, it is important to underscore that there are
patients with decreased serum l-asparaginase activity and no
demonstrable IgG antibodies to the enzyme, suggesting that
additional factors are involved in this phenomenon. These
factors include the number of doses and intensity of the l-
asparaginase regimen, concomitant administration of strong
immunosuppressive drugs as part of the chemotherapeutic
regimen and enhanced enzyme clearance associated to pro-
tease degradation.
It is noticeable that given the frequency and severity of
reactions to l-asparaginase in children with ALL, few stud-
ies have analyzed the correlation of IgE with clinical events.
The current study found a prevalence for positive skin tests
of 63% (32/51) employing the PST and IST, although only
three of these children (9.4%) developed hypersensitivity reac-
tions, suggesting that production of IgE anti-l-asparaginase
antibodies mostly occurs silently.28 In this respect, allergen-
speciﬁc IgE antibodies are responsible for sensitizing mast
cells and recognizing allergens in immediate hypersensitiv-
ity reactions. IgE binds to eosinophils, basophils and masthistamine, prostaglandin and cytokines, which mediate clin-
ical hypersensitivity symptoms. The low frequency of allergic
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eactions in the children of this study could be related to
he routine practice in our institution of pre-medication with
nti-histamines to prevent allergic reactions to the enzyme,
he low-dose l-asparaginase regimen used (6000 IU/M2 com-
ared to 10,000 IU/M2 in other reports)8,13,21 and the lower
edian number of l-asparaginase doses [8 (range: 5–15) com-
ared to 13.5 (range: 4–20) in other reports]. Both dose and
umber of doses are directly related to the development of
ypersensitivity events.3 Interestingly, despite the fact that
igh-risk ALL children received more  l-asparaginase doses
han standard-risk patients (9 vs. 6), there was no difference
n the rate of anti-l-asparaginase antibodies produced. We
ypothesize that this could be due to the existence of a criti-
al threshold of immunizing events to l-asparaginase, beyond
hich l-asparaginase-non-responders remain antibody-free.
enetic factors may inﬂuence the likelihood of develop-
ng clinical hypersensitivity reactions; using a genome-wide
pproach, it was reported that genetic variations in GRIAI were
ssociated with asparaginase allergies.29
The basophil activation test (BAT), in which the surface
xpression of the degranulation/activation marker (CD203c)
n basophils is detected, is considered a reliable tool for diag-
osing IgE-mediated allergies. Recently, it has been shown
hat BAT is a useful marker for identifying l-asparaginase
llergy because of its high sensitivity and speciﬁcity, and com-
ining the BAT with an l-asparaginase-speciﬁc IgG assay is the
ost accurate method of identifying l-asparaginase allergy.30
This study found a positive correlation between the pres-
nce of IgG anti-l-asparaginase antibodies and ALL relapse,
onﬁrming previous studies that found a negative inﬂuence
f neutralizing IgG antibodies, manifested as lower EFS and
verall survival.1,3,15 Remarkably, the presence of IgE antibod-
es documented by skin testing was not associated to a higher
elapse rate. This is probably because this class of antibod-
es lacks neutralizing activity; on the contrary, there was an
ssociation between negative skin tests and elevated risk of
dditional relapses. Thus, children who suffered a ﬁrst relapse
nd had negative skin tests had a statistically signiﬁcant
ncreased risk of subsequent relapses: 55% compared to 0%
n those with positive skin tests (p-value < 0.0001). We  hypoth-
size that children with more  than one relapse and negative
kin tests might have additional defective immune surveil-
ance and blunting of the critical process of host-dependent
econdary elimination of the residual leukemic clone, thereby
avoring ALL relapses. In this respect, both, humoral and cel-
ular immune functions are decreased during ALL and its
herapy31; regaining immune function can take several years
o accomplish, and even then, the recovery of IgG subclasses
an be impaired.32 Additionally, relapsed children with IgE
ntibodies may have a limited capacity to produce IgG neu-
ralizing antibodies and then have a lower risk of relapse.
The hypothesis that children with IgG anti-l-asparaginase
ntibodies, in isolation or associated with IgE antibodies,
ould clear the drug from the blood and children would
elapse more  frequently than those without IgG antibodies
as not conﬁrmed by Kaplan–Meier analysis (p-value = 0.774).n addition, the hypothesis that IgE anti-l-asparaginase anti-
odies, alone or in combination with IgG antibodies, would
e detrimental because children who  developed IgE antibod-
es would not receive the same amount of l-asparaginase due 1 7;3  9(3):202–209 207
to supervening allergic reactions was not conﬁrmed. On the
contrary, IgE seemed to protect children with this antibody,
alone or in combination with IgG antibodies (p-value = 0.024).
Accordingly, IgE might play a dual role in ALL, as a negative
factor due to its participation in hypersensitivity reactions,
forcing the cessation of therapy and the switching of enzyme
preparations, or as a positive surrogate indicator for residual
immune competence and less additional relapses. Moreover,
there is the possibility of some interaction, either positive or
negative, between the effects of IgG and IgE antibodies. These
results appear equivocal, which may be due to the small num-
ber of children in each group; the literature however, does
not offer a deﬁnitive answer in this respect yet and interest-
ingly, there are no studies documenting a link between the
presence of IgE anti-l-asparaginase antibodies and decreased
serum activity of l-asparaginase. The last consensus recom-
mendations consider that the development of either antibody
is detrimental to children with ALL.12 However, when the cur-
rent small group was analyzed, no signiﬁcant difference was
found, although the comparison showed a higher EFS, albeit
non-signiﬁcant (p-value = 0.583), in the no-antibodies group
(n = 9; median 68 months) vs. those with any type of antibody
(n = 42; median 45 months). These results suggest that there
are different implications according to the class of antibody
present. IgG antibodies are associated to a bad prognosis and
IgE has either a negative association due to hypersensitiv-
ity reactions, or a positive association conferring resistance
to subsequent relapses, probably as a surrogate indicator of
residual immune competence in children, leading to ﬁnal
clearance of the leukemic clone.
Limitations in our proof-of-concept study include the small
sample size and its retrospective design. Additionally, the
relapse rate was higher than expected, reﬂecting the fact that
most patients referred to our center have unfavorable clinical
and hematologic characteristics at diagnosis and were treated
with a low-moderate dose intensity protocol, as well as the
known greater incidence of high-risk children in the Hispanic
population.33 Another major limitation is the heterogeneity
of the clinical stages at the time of the single determination
of IgG and IgE antibodies for this cross-sectional, proof-of-
concept study, and thus in order to conﬁrm these ﬁndings
a prospective, sufﬁciently powered study, including balanced
groups at all major time points of treatment, is required.
In conclusion, children with only IgG antibodies against
l-asparaginase suffered more  relapses than those without
these antibodies or when IgE was simultaneously present and
patients with IgE positive skin tests for the enzyme had a
decreased risk of suffering more  than one relapse. Forty-ﬁve
years after the initial report,34 critical aspects of the immune
response to l-asparaginase in ALL are still undeﬁned; prospec-
tive studies aimed at deciphering the intricate nature of this
response mediated by IgG and IgE antibodies are necessary to
deﬁnitively establish their interactions and inﬂuence on the
outcomes of ALL of childhood.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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